DDInter1033 DDInter922
Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.
Inappropriate growth of or self-directed antibody production by B-cells is the etiological underpinning of a variety of conditions, including the multiple sclerosis-like neurological condition neuromyelitis optica spectrum disorder (NMOSD).[A214283, A214286] Inebilizumab is a humanized afucosylated monoclonal IgG1 antibody directed against the broadly expressed B-cell surface antigen CD19. Inebilizumab is cytolytic, resulting in B-cell depletion and offering therapeutic benefit to patients suffering from NMOSD. Compared to the anti-CD20 antibody [rituximab], which is also used to treat NMOSD, inebilizumab has broader specificity.[A214280, A214289, A214292, A214295, A214298, A214301] Inebilizumab was granted FDA approval on June 11, 2020, for the treatment of anti-aquaporin 4 positive NMOSD patients. Given its mechanism of action and good safety profile, it may prove useful in the treatment of other conditions linked to autoimmune antibody production or B-cell malignancies.[A214280, A214295] On January 16, 2024, Iinebilizumab also received Health Canada approval for the same indication.
Leflunomide {u} (Compound) resembles {v} (Compound) Niflumic Acid
Leflunomide {u} (Compound) treats {v} (Disease) systemic scleroderma
Leflunomide {u} (Compound) binds {v} (Gene) PTK2B
Leflunomide {u} (Compound) upregulates {v} (Gene) WIF1
Leflunomide {u} (Compound) downregulates {v} (Gene) MRPS16
Leflunomide {u} (Compound) causes {v} (Side Effect) Skin nodule
Leflunomide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Leflunomide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Leflunomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clostridium tetani toxoid antigen (formaldehyde inactivated)
Leflunomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Losartan
Leflunomide (Compound) resembles Niflumic Acid (Compound)
Leflunomide (Compound) treats systemic scleroderma (Disease)
Leflunomide (Compound) binds PTK2B (Gene)
Leflunomide (Compound) upregulates WIF1 (Gene)
Leflunomide (Compound) downregulates MRPS16 (Gene)
Leflunomide (Compound) causes Skin nodule (Side Effect)
Leflunomide may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Leflunomide may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Losartan